Atherothrombosis-on-Chip: A Site-Specific Microfluidic Model for Thrombus Formation and Drug Discovery

Adv Biol (Weinh). 2022 Jul;6(7):e2101316. doi: 10.1002/adbi.202101316. Epub 2022 Jun 4.

Abstract

Atherothrombosis, an atherosclerotic plaque disruption condition with superimposed thrombosis, is the underlying cause of cardiovascular episodes. Herein, a unique design is presented to develop a microfluidic site-specific atherothrombosis-on-chip model, providing a universal platform for studying the crosstalk between blood cells and plaque components. The device consists of two interconnected microchannels, namely main and supporting channels: the former mimics the vessel geometry with different stenosis, and the latter introduces plaque components to the circulation simultaneously. The unique design allows the site-specific introduction of plaque components in stenosed channels ranging from 0% to above 50%, resulting in thrombosis, which has not been achieved previously. The device successfully explains the correlation between vessel geometry and thrombus formation phenomenon as well as the influence of shear rate on platelet aggregation, confirming the reliability and the effectiveness of the design. The device exhibits significant sensitivity to aspirin. In therapeutic doses (50 × 10-6 and 100 × 10-6 m), aspirin delays and prevents platelet adhesion, thereby reducing the thrombus area in a dose-dependent manner. Finally, the device is effectively employed in testing the targeted binding of the RGD (arginyl-glycyl-aspartic acid) labeled polymeric nanoparticles on the thrombus, extending the use of the device to examine targeted drug carriers.

Keywords: atherosclerosis; atherothrombosis; chips; microfluidic; plaques; platelets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspirin
  • Drug Discovery
  • Humans
  • Microfluidics
  • Plaque, Atherosclerotic* / drug therapy
  • Reproducibility of Results
  • Thrombosis* / drug therapy

Substances

  • Aspirin